Ozempic for Weight Loss: How GLP-1 Drugs Work and Their Side Effects

In Clinical Trials, Semaglutide Produced 15% Body Weight Loss in 68 Weeks

Ozempic's active ingredient, semaglutide, was approved by the FDA in 2017 for type 2 diabetes management. When the STEP 1 trial results arrived in 2021, showing adults with obesity losing an average of 14.9% of body weight over 68 weeks using the higher 2.4 mg dose, it became clear this drug class was going to reshape medicine far beyond endocrinology. Ozempic itself remains FDA-approved only for type 2 diabetes — it's the 2.4 mg formulation marketed as Wegovy that holds the obesity indication. But semaglutide is semaglutide, and off-label Ozempic prescriptions for weight loss became ubiquitous, creating global supply shortages of a drug diabetic patients depend on.

The GLP-1 Mechanism: More Than Just Appetite Suppression

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the gut after meals. It performs multiple metabolic functions that semaglutide mimics and amplifies.

• Pancreatic beta cells: Stimulates glucose-dependent insulin secretion — insulin only releases when blood glucose is elevated, reducing hypoglycemia risk
• Pancreatic alpha cells: Suppresses glucagon release, preventing excess liver glucose production
• Gastric emptying: Slows how quickly food leaves the stomach, blunting post-meal glucose spikes and prolonging satiety signals
• Hypothalamic appetite centers: GLP-1 receptors in the brain's arcuate nucleus reduce hunger signaling and food-reward motivation
• Cardiovascular tissue: Direct cardioprotective effects on heart muscle and arterial endothelium — the mechanism behind impressive CV outcome trial results

Semaglutide's half-life of approximately 7 days (versus native GLP-1's 2-minute half-life) makes once-weekly dosing possible. This pharmacokinetic advantage comes from molecular modifications: substituting one amino acid and attaching a fatty acid chain that binds albumin in the bloodstream.

What Ozempic Is Actually Approved For

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved for three specific indications in adults with type 2 diabetes: to improve glycemic control, to reduce the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease, and to reduce the risk of chronic kidney disease progression (added in 2024 based on the FLOW trial). It is not FDA-approved for weight loss as Ozempic. Wegovy uses the same molecule at 2.4 mg.

Clinical Evidence for Weight Loss

The STEP 4 trial finding — that discontinuing semaglutide led to significant weight regain — framed the drug as a chronic treatment, not a course. Most weight returns within a year of stopping, which has major implications for insurance coverage and long-term prescribing strategy.

Documented Side Effects

The gastrointestinal side effect profile is the drug's most significant limitation, and it's dose-dependent. Symptoms typically peak during dose escalation and improve over weeks.

Serious but Rare Risks

Pancreatitis is an FDA black-box-adjacent concern: GLP-1 drugs carry a warning about acute pancreatitis risk, though rates in large trials were not significantly elevated versus placebo. More concerning is the rodent study finding of thyroid C-cell tumors at high doses — the basis for a black box warning about medullary thyroid carcinoma (MTC) risk. This remains a theoretical human concern; no causal link has been established in humans, but the drug is contraindicated in anyone with personal or family history of MTC or Multiple Endocrine Neoplasia Type 2. Gastroparesis — pathologically delayed gastric emptying — has been reported with prolonged use and poses surgical anesthesia risks if patients do not fast adequately before procedures.

"Ozempic Face" and Muscle Loss

Rapid weight loss from any cause, including semaglutide, can produce facial volume loss — colloquially called "Ozempic face." More clinically relevant is muscle mass loss. Semaglutide trials showed roughly 38% of weight lost was lean mass rather than fat, compared to roughly 20–25% lean mass loss with lifestyle intervention alone. Preserving muscle requires adequate protein intake (1.2–1.6 g/kg/day) and resistance training during treatment.

Real-World Considerations

At list price, Ozempic costs approximately $935/month in the United States without insurance. Insurance coverage varies widely and is frequently denied for non-diabetic use. Compounded semaglutide from 503B pharmacies proliferated during the shortage period, but FDA removed semaglutide from the shortage list in 2025, making compounded versions legally problematic. The drug's long-term safety beyond 3–4 years of observation remains under study, with the SELECT trial providing some of the longest available data at approximately 3.3 years.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.